Federated Hermes Inc. reduced its stake in shares of Teleflex Incorporated (NYSE:TFX - Free Report) by 11.1% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 52,428 shares of the medical technology company's stock after selling 6,547 shares during the period. Federated Hermes Inc. owned about 0.11% of Teleflex worth $7,245,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. CANADA LIFE ASSURANCE Co grew its holdings in shares of Teleflex by 0.4% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 20,320 shares of the medical technology company's stock valued at $3,614,000 after acquiring an additional 74 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its holdings in shares of Teleflex by 103.1% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 197 shares of the medical technology company's stock valued at $27,000 after acquiring an additional 100 shares in the last quarter. True Wealth Design LLC grew its holdings in shares of Teleflex by 62.3% in the fourth quarter. True Wealth Design LLC now owns 271 shares of the medical technology company's stock valued at $48,000 after acquiring an additional 104 shares in the last quarter. Signaturefd LLC grew its holdings in shares of Teleflex by 38.3% in the first quarter. Signaturefd LLC now owns 433 shares of the medical technology company's stock valued at $60,000 after acquiring an additional 120 shares in the last quarter. Finally, Empirical Finance LLC grew its holdings in shares of Teleflex by 7.9% in the first quarter. Empirical Finance LLC now owns 1,690 shares of the medical technology company's stock valued at $234,000 after acquiring an additional 124 shares in the last quarter. 95.62% of the stock is owned by institutional investors.
Teleflex Stock Performance
Shares of NYSE:TFX traded down $3.63 during trading on Friday, hitting $115.87. 642,835 shares of the company were exchanged, compared to its average volume of 567,643. The company has a market cap of $5.12 billion, a PE ratio of 27.26, a P/E/G ratio of 1.72 and a beta of 1.08. The stock has a 50 day moving average of $118.73 and a 200 day moving average of $136.89. Teleflex Incorporated has a 52-week low of $108.90 and a 52-week high of $249.90. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.41 and a quick ratio of 1.44.
Teleflex (NYSE:TFX - Get Free Report) last posted its earnings results on Thursday, July 31st. The medical technology company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.36 by $0.37. The firm had revenue of $780.90 million for the quarter, compared to the consensus estimate of $771.53 million. Teleflex had a return on equity of 15.08% and a net margin of 6.31%. The business's quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.42 earnings per share. As a group, equities research analysts predict that Teleflex Incorporated will post 13.98 EPS for the current year.
Teleflex Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 15th. Investors of record on Friday, August 15th will be given a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Friday, August 15th. Teleflex's dividend payout ratio (DPR) is 32.00%.
Analyst Ratings Changes
Several equities analysts have recently issued reports on the company. Wells Fargo & Company reduced their target price on Teleflex from $137.00 to $131.00 and set an "equal weight" rating for the company in a report on Friday. Mizuho upped their target price on Teleflex from $130.00 to $135.00 and gave the company a "neutral" rating in a report on Friday. Wall Street Zen raised Teleflex from a "hold" rating to a "strong-buy" rating in a report on Saturday. Truist Financial decreased their target price on Teleflex from $140.00 to $137.00 and set a "hold" rating for the company in a research report on Monday, May 5th. Finally, Morgan Stanley decreased their target price on Teleflex from $191.00 to $173.00 and set an "overweight" rating for the company in a research report on Monday, May 5th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Teleflex presently has an average rating of "Hold" and a consensus price target of $141.57.
View Our Latest Stock Report on TFX
Teleflex Company Profile
(
Free Report)
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.
Further Reading

Before you consider Teleflex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teleflex wasn't on the list.
While Teleflex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.